Increased NEK2 in hepatocellular carcinoma promotes cancer progression and drug resistance by promoting PP1/Akt and Wnt activation

SAILAN WEN1,2, YUWU LIU3, MANYI YANG4, KEDA YANG5, JIANGHAI HUANG1,2 and DEYUN FENG2,5

1Department of Pathology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011; 2Department of Pathology, School of Basic Medical Sciences, Central South University, Changsha, Hunan 410013; 3Department of Morphology, The Institute of Advanced Occupation Technology, Xinjiang Medical University, Urumqi, Xinjiang 830011; 4National Hepatobiliary and Enteric Surgery Research Center, Department of Surgery, Xiangya Hospital, Central South University, Changsha, Hunan 410008; 5Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China

Received March 1, 2016; Accepted July 13, 2016

DOI: 10.3892/or.2016.5009

Abstract. NIMA-related expressed kinase 2 (NEK2) participates in the carcinogenesis and progression of certain types of cancer, however, its expression and roles in the development of hepatocellular carcinoma (HCC) remains unknown. Here, we found that NEK2 expression was significantly upregulated in both human HCC tissues and cell lines, and increased NEK2 expression in HCC was significantly correlated with clinical progression of HCC in patients. Knockdown of NEK2 in HCC cells inhibited HCC progression, as determined by the suppressed cell proliferation, invasion and metastasis. Furthermore, knockdown of NEK2 inhibited drug resistance of HCC cells, as shown by the promoted suppression of cell viability in 5-fluorouracil (5-FU)-treated HCC cells. Mechanistically, protein phosphatase 1 (PP1)/Akt and Wnt signaling activation are significantly inhibited by NEK2 knockdown, which is responsible for the HCC progression and involved in NEK2-induced cancer cell abnormal biological behavior. Thus, enhanced NEK2 expression in HCC promotes HCC progression and drug resistance by promoting PP1/Akt and Wnt pathway activation, which may represent a new therapeutic target for HCC.

Introduction

Hepatocellular carcinoma (HCC) is a highly aggressive and heterogeneous disease, and is among the leading causes of cancer-related deaths, especially in China (1). Although clinical treatments of HCC have been developed, uncontrolled metastasis and high recurrence lead to poor prognosis of HCC patients. A major reason for HCC-treatment failure is the existence of a drug-resistant subclone, either presenting at diagnosis or development during treatment. Therefore, it is urgent to achieve new treatment options for HCC and explore the molecular mechanisms underlying carcinogenesis and progression of HCC.

NIMA-related expressed kinase 2 (NEK2) as one of chromosomal instability (CIN) genes, is a member of the serine-threonine kinase family NEK, and functional studies have implicated that NEK2 is involved in cell division and mitotic regulation by centrosome splitting (2,3). Increased expression of NEK2 has been reported in certain cancers, such as breast, cervical, prostate carcinomas, lung cancer, and lymphoma, suggesting the involvement of NEK2 in cancer development (4-8). Additionally, NEK2 has been proven to play pivotal roles in cell proliferation and drug resistance of cancer cells with poor prognosis in myeloma, in which both protein phosphatase 1 (PP1)/Akt and Wnt pathways are involved (9). According to the current network-based interpretation of transcript expression level, NEK2 was significantly elevated in HCC patients compared to normal controls (10). However, despite these studies, the roles of NEK2 in HCC carcinogenesis and progression, especially for drug resistance still remain unknown.

In this study, we investigated the role of NEK2 in HCC development. We found that NEK2 is significantly increased in both HCC tissues and cell lines, and participates in HCC progression and drug resistance. Mechanistically, PP1/Akt and Wnt signaling activation are significantly inhibited by NEK2 knockdown, which implicates the role of NEK2 in promoting HCC progression. Collectively, our data show that enhanced NEK2 expression promotes HCC progression and drug resistance by promoting PP1/Akt and Wnt pathway activation, which may represent a new therapeutic target for HCC.
Materials and methods

Clinical samples. There were 64 patients who underwent resection for HCC between 2011 and 2012 at the Department of Hepatobiliary Surgery, the Second Xiangya Hospital of Central South University. None of these patients received chemotherapy or radiotherapy before the operation. The group was composed of 52 men and 12 women at the time of operation. A summary of patient characteristics and pathological features is presented in Table I. Tumor specimens were either cut immediately after removal from the resected hepatic tissues, frozen in liquid nitrogen, and then stored at -80˚C or collected in 10% formalin and then embedded in paraffin for histopathological analysis.

Antibodies, reagents and RNA interference. Phos-Akt (Ser473), Akt (C67E7) rabbit nuclear factor-kB (NF-kB) p65 (D14E12), phos-NF-kB p65 (Ser536), phos-GSK3 (Ser9), β-catenin (D10A8) and β-actin (8H10D10) used for immunoprecipitation were from Cell Signaling Technology, Inc. Antibodies to NEK2 (ab55550) for western blotting and immunocytochemistry were from Abcam (Cambridge, MA, USA). All other reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA) except for MTT (5 mg/ml) (Sigma-Aldrich, St. Louis, MO, USA). Non-specific control siRNA (5′-AAG TAG CCG AGCT AUG CUU GUU-3′) and siRNA3 (5′-UCU GUU GAA GAA GUA CAG CUU-3′) were purchased from GenePharma Co., Ltd., and transfected into the cells using Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer's instructions. Non-specific control siRNA (5′-AAG TAG CCG AGCT TCG ATT GC-3′) was also used.

Cell culture. HepG2, BEL-7402, QGY-7703, SMMC7721 and HuH-7 were from the Institute of Biochemistry and Cell Biology (Shanghai Institutes for Biological Sciences, CAS). Cells were cultured in RPMI-1640 (Gibco, 31800022; 1.5 g/l NaHCO3, 2.5g/l glucose, 0.11g/l sodium pyruvate) supplemented with 10% fetal calf serum (FCS; Invitrogen) in a humidified incubator under 5% CO2 at 37˚C.

Cell proliferation and half maximal inhibitory concentration (IC50) values. Cell proliferation was determined using MTT assay of cell proliferation as described before (11). Cells were cultured into a 96-well plate at 1x104 cells/well (n=4 for each time point) in a final volume of 100 µl. Cells were cultured for 36-48 h after transfection with NEK2-siRNA and ctrl-siRNA (non-specific control siRNA), respectively. Then, 20 µl MTT (5 mg/ml) was added to each well (0.8 mg/ml final concentration) for further incubation for 4 h. Then the medium was removed, and 100 µl DMSO was added to dissolve the solid formazan for 15 min. The absorbance of each well was read at 490 nm using a microplate reader (Thermo Fisher Scientific, Inc.). For drug resistance assay, cells were stimulated with different concentrations (0, 0.25, 0.5, 1, 20, 50 and 100 µg/ml) of 5-FU in culture medium for 48 h after transfection with siRNA. The IC50 values were calculated by non-linear regression analysis using SPSS 17.0 software (SPSS, Chicago, IL, USA) as before (12).

In vitro cell-invasion and -migration assays. Migration and invasion assay Transwell filters coated with collagen I or Matrigel (8-mm pore size; BD Biosciences) were used for migration or invasion assays, respectively. Cells (1.5x104) were seeded into the upper chamber in RPMI-1640 with 0.5% fetal bovine serum (FBS). The bottom chamber contained RPMI-1640 with 10% FBS. Cells were allowed to migrate/invade at 37˚C in 5% CO2 for 24 h before they were fixed with methanol/methylene blue solution, stained with crystal violet (Beyotime, Shanghai, China) and quantified with ImageJ software (13).

Table I. Relationship between NEK2 expression and clinicopathological features of HCC.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Total</th>
<th>NEK2</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No.</td>
<td>%</td>
</tr>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤50</td>
<td>33</td>
<td>51.6</td>
</tr>
<tr>
<td>&gt;50</td>
<td>31</td>
<td>48.4</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>52</td>
<td>81.2</td>
</tr>
<tr>
<td>Female</td>
<td>12</td>
<td>18.8</td>
</tr>
<tr>
<td>HBV</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>53</td>
<td>82.8</td>
</tr>
<tr>
<td>Negative</td>
<td>11</td>
<td>17.2</td>
</tr>
<tr>
<td>Serum AFP (ng/ml)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤400</td>
<td>49</td>
<td>76.6</td>
</tr>
<tr>
<td>&gt;400</td>
<td>15</td>
<td>23.4</td>
</tr>
<tr>
<td>Differentiation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>7</td>
<td>10.9</td>
</tr>
<tr>
<td>2</td>
<td>15</td>
<td>23.4</td>
</tr>
<tr>
<td>3</td>
<td>42</td>
<td>75.7</td>
</tr>
<tr>
<td>Tumor size (cm)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤5</td>
<td>19</td>
<td>29.7</td>
</tr>
<tr>
<td>&gt;5</td>
<td>45</td>
<td>70.3</td>
</tr>
<tr>
<td>Tumor no.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Single</td>
<td>56</td>
<td>87.5</td>
</tr>
<tr>
<td>Multiple</td>
<td>8</td>
<td>12.5</td>
</tr>
<tr>
<td>Lymph node metastasis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>5</td>
<td>7.8</td>
</tr>
<tr>
<td>Negative</td>
<td>59</td>
<td>92.2</td>
</tr>
<tr>
<td>Hepatic sclerosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>30</td>
<td>46.9</td>
</tr>
<tr>
<td>No</td>
<td>34</td>
<td>53.1</td>
</tr>
</tbody>
</table>

*Significantly different. NEK2, NIMA-related expressed kinase 2; HCC, hepatocellular carcinoma.
All experiments were performed in triplicate. Cell counts were performed on 10 fields per filter, and the mean was normalized to the migration/invasion cell count of control cells.

Quantitative real-time PCR. Total RNA was extracted with TRIzol reagent (Invitrogen) following the manufacturer’s instructions. Real-time quantitative RT-PCR analysis was performed using the LightCycler (Roche Diagnostics) and SYBR RT-PCR kits (Takara Biotechnology Co., Ltd.). For mRNAs analysis, the primers were: human NEK2 forward, 5'-CCG CCC AAG TCA CAG CAG CAGA-3' and reverse, 5' -GGG AGA AGA GCA GCA GCA AGC-3'; human β-actin forward, 5'-CAT CCT GCG TCT GGA CCT GG -3' and reverse, 5'-TAA TGT CAC GCA CGA TTT CG-3'; human ABCB1 forward, 5'-AGG CTC GCC AAT GAT GC -3' and reverse, 5'-TCC TGT CCT CCC AAG ATT TGC TAT-3'; human ABCG2 forward, 5'-TGA AAC CTG GTC TCA ACGC-3' and reverse, 5'-AGG CTC GCC AAT GCT TCC TGT CCT CCC AAG ATT TGC TAT-3'; human ABCC1 forward, 5'-CGC CTT CGC TGA GTT CCT GC-3' and reverse, 5'-AGT TCT GCG GTG CGC TTA GTC TGG-3'. The relative expression level of mRNAs was normalized to that of internal control GAPDH by using 2⁻ΔΔCt cycle threshold method (13).

Cell extraction, protein electrophoresis, and western blotting. Whole cell lysates of QGY-7703 cells were prepared in radioimmunoprecipitation assay buffer [50 mmol Tris-HCl (pH 8.0), 150 mmol NaCl, 1% NP40, 0.5% sodium deoxycholate, and 0.1% SDS]. Briefly, cells were washed in ice-cold 1X PBS (pH 7.4) and lysed directly in radioimmunoprecipitation assay buffer on ice for 30 min, centrifuged at 4°C, 14,000 rpm, to remove insoluble material and total protein concentration of the resulting supernatant determined by bichinonic acid assay (Pierce Biotechnology, Inc., Rockford, IL, USA). Lysate, 50 µg, for each cell line was resolved by sodium dodecyl-sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). For immunoblot analysis, protein samples were subjected to SDS-PAGE and transferred onto a nitrocellulose membrane. The membrane was incubated with a primary antibody overnight at 4°C after blocking with 5% skim milk in 0.1% TBST (Tris-buffered saline with 0.1% Triton X-100) for 60 min. The second day, the membrane was incubated with a horseradish peroxidase-conjugated secondary antibody for 60 min after washing three times with 0.1% TBST, then, the membrane was incubated with the ECL solution after washing three times with 0.1% TBST, and exposed to X-ray film.

Immunocytochemistry and image processing. Immunohistochemical studies on NEK2 were performed on formalin-fixed, paraffin-embedded tissue sections obtained from the aforementioned patients with HCC. Tissue sections were deparaffinized and then boiled in 0.01 mol/l sodium citrate buffer (pH 6.0) in a 1,000 W microwave oven for 10 min to retrieve cell antigens. The primary antibody used was rabbit
polyclonal NEK2 antibody (1:200 dilution; Bioss, China). All tissue sections were immunohistochemically stained using the avidin-biotin-peroxidase method and were counterstained with hematoxylin. The staining was scored by three independent investigators without knowledge of patient outcomes. The sections were evaluated at low magnification (x100 or x200) to identify areas where NEK2 was evenly stained.

**Statistical analysis.** The data were subjected to statistical analysis using the SPSS software package (version 17.0). The clinicopathological parameters were tested by χ² test and bivariate analysis (14). All data are presented as the mean ± SD. The statistical differences were analyzed by Student's t-test and repeated measures of ANOVA. The differences were considered to be statistically significant at P<0.05.

**Results**

*NEK2 expression is significantly elevated in HCC.* NEK2 is considered an oncogene and is overexpressed in various tumors (8,15,16). In order to examine the roles of NEK2 in HCC development, we examined the expression of NEK2 in HCC tissues and cell lines. As shown in Fig. 1A, compared with negative control HFF (human fibroblast cell line), in HCC cell lines HepG2, BEL-7402, QGY-7703, SMMC7721 and Huh-7, we found that NEK2 was highly expressed. Furthermore, NEK2 expression was significantly increased in HCC tissues as compared to that in the matched non-tumor tissues. Hence, these data confirm that NEK2 expression is significantly increased in both HCC tissues and cell lines, which indicates an important role in HCC carcinogenesis and progression.

We further examined the correlation between NEK2 and the clinicopathological characteristics of patients with HCC. As summarized in Table I, NEK2 expression was not significantly correlated with age or histological grades. However, NEK2 expression was significantly correlated with tumor size, differentiation grading and lymph node metastasis (P=0.001, 0.045 and 0.029). Together, these data suggest that elevated NEK2 expression in HCC is correlated with the clinical progression of HCC patients.

*NEK2 promotes proliferation of HCC cells.* As NEK2 expression is increased in HCC, we next investigated the roles of NEK2 increase in HCC development. RNA interference has emerged as natural and highly efficient mechanism for gene silencing (17-19). In order to test the functional role of NEK2 on cell growth, we have designed three siRNA candidates based on NEK2 gene sequence. Real-time PCR confirmed a remarkable downregulation of NEK2 expression in QGY-7703 cells after transfection of these NEK2-siRNAs (Fig. 2A). Additionally,
relative amounts of NEK2 protein were decreased by siRNA1, 2 and 3 respectively, compared with those of control siRNA-treated cells (Fig. 2B). In contrast, transfection with control siRNA did not alter NEK2 expression significantly.

We then examined the effect of NEK2 knockdown on cell growth of QGY-7703 cells. As shown in Fig. 2C, the growth of QGY-7703 cells was substantially suppressed by treatment with NEK2 siRNA1 or 3 compared with control siRNA-treated cells. The results indicate that NEK2 can promote HCC cell proliferation.

NEK2 promotes migratory and invasive capacities of HCC cells. Because NEK2 controls microtubule organization, over-expressed NEK2 might affect tumor invasion and migration. Therefore, we studied the effect of NEK2 siRNA administration on the invasion and migration of HCC cells. Compared with their control cells and control siRNA-treated cells, knockdown of NEK2 markedly reduced the invasion of QGY-7703 cells (Fig. 3A and B), and also showed significantly impaired migration of QGY-7703 cells (Fig. 3C and D), suggesting that knockdown of NEK2 may dampen the microtubule organization to inhibit their mobility potential. Together with the role of NEK2 in the promotion of HCC proliferation, we conclude that NEK2 promotes HCC progression.

NEK2 knockdown frustrates drug resistance of HCC cells. We subsequently tested if knockdown of NEK2 expression could decrease drug resistance to fluorouracil injection (5-FU) using insensitive SMMC7721 cell lines. 5-FU inhibited cell proliferation of the SMMC7721 cell lines in a dose-dependent manner (Fig. 4A). Results of IC₅₀ from the representative SMMC7721 were 51.1±4.70, 48.69±2.57 and 15.61±1.85 µg/ml in SMMC7721 cells non-treated, treated with ctrl-siRNA or NEK2-siRNA, respectively (Fig. 4B). SMMC7721 cells with NEK2 knockdown showed a significant decrease of IC₅₀, indicating that highly elevated NEK2 could promote drug resistance to 5-FU.

NEK2 activates both Akt and canonical Wnt signaling. NEK2 is known to regulate the mitotic centrosome separation through reversible phosphorylation of its substrates PP1 (20) and β-catenin (21) in yeast, which is also important for cancer cell drug resistance and proliferation (9). Another study demonstrated that the transcriptional level of NEK2 is increased in many aggressive types of cancer, and at least two pathways, PP1/Akt and Wnt signaling, are involved in NEK2-induced cancer cell progression and drug resistance. Consistently, knockdown of NEK2 by siRNA impaired the phosphorylation of Akt, glycogen synthase kinase-3 (GSK3), NF-κB and...
decreased nuclear β-catenin (Fig. 5A), which activates drug resistance and pro-survival gene members. Furthermore, we found that knockdown of NEK2 downregulated mitotic checkpoint protein ABC transporter family members, including ABCB1, the drug resistance protein ABCC1 (MRP1), and the breast cancer resistant protein ABCG2 (BCRP) (Fig. 5B). In addition, knockdown of NEK2 decreased the expression of pro-survival gene members of the BCL2 family (BCL2 and MCL1) in SMMC7721 cell lines, while promoted the pro-apoptotic gene members BAD and BAX, which are suppressed by Akt (Fig. 5C). These results strongly suggest that PP1 and β-catenin are the downstream targets of NEK2 in HCC cells, and increased NEK2 could contribute to HCC progression by amplifying the PP1/Akt and Wnt pathway.

Discussion

HCC is the third most common cause of cancer-related deaths worldwide (22,23). NEK2, a member of the NIMA-related family, has several putative roles in cell differentiation, proliferation by centrosome splitting (3,24). Overexpression of active NEK2 leads to CIN, cell proliferation and drug resistance, which are also commonly observed in cancers including virtually all myelomas (9,25). Our study showed that centrosomal kinase NEK2 expression was significantly upregulated in HCC cell lines and tissues (Fig. 1). According to Table I, NEK2 expression is correlated with tumor size, differentiation grading and lymph node metastasis, which suggests that NEK2 participates in the clinical progression of HCC patients. Our data also shown that NEK2 is mostly positive in the cytoplasm of the HCC tissue cells and promotes HCC progression and
drug resistance by amplifying the PP1/Akt and Wnt signaling pathway.

In this study, we found that two pathways, PP1/Akt and Wnt signaling, are involved in NEK2-induced cancer cell progression. It has been revealed that PP1 regulates the Akt signaling pathway to control cell survival, invasion and migration (26,27). Akt functions through IKK to promote the transactivation potential and phosphorylation of NF-κB (28), which activates transcription of pro-survival gene members of the BCL2 family. In the cytoplasm, GSK3 forms a β-catenin destruction complex which mediates the degradation of β-catenin, which is important for constitutive activation of the canonical Wnt signaling pathway and drives cell proliferation by direct induction of cell cycle regulators (29,30). Our findings support that NEK2 promotes the expression of phosphorylated Akt, GSK3, NF-κB and increases nuclear accumulation of β-catenin. Furthermore, we found that knockdown of NEK2 decreased the expression of ABC transporters, resulting in inhibited drug resistance of HCC cells. Additionally, drug resistance is a universal problem with current cancer therapies. CIN genes have also been associated with acquired or intrinsic drug resistance (31). We demonstrated that targeting NEK2 overcame drug resistance and cell growth of SMMC7721 cells to 5-FU.

In summary, elevated expression of NEK2 in HCC results in both impaired PP1/AKT and Wnt pathways, which are involved in NEK2-induced cancer cell drug resistance, invasion, migration and proliferation. Knockdown of NEK2 by siRNA inhibited QGY-7703 cell growth and decreased drug resistance in vitro. Thus, targeting CIN genes, such as NEK2, have the potential to translate into very important prognostic and therapeutic clinical tools. We are now exploring how NEK2 regulates its downstream targets and how interaction among those pathways is regulated by NEK2 in HCC.

Acknowledgements

This study was supported by the National Natural Science Foundation of China (81402001). We thank Professor Lifang Yang and Daqiang Li for their excellent technical assistance.

References